Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Diabete Type 2
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Evaluate from a clinical and microbiological point of view the effect of an adjunctive therapy based on a thermal-gelling device Pocket-X® Gel (Hyaluronic acid, Poloxamer, 2-Phenoxyethanol, Octedine HCL, Water), in the non-surgical treatment of periodontal defects, in a population of patients with T2DM compared to non-diabetic patients. Determine whether periodontal defect healing is clinically and microbiologically different between T2DM patients and non-diabetic patients; whether periodontal treatment and maintenance can lead to improvement of conditions and stability over time also for diabetic conditions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Gel therapy after non surgical therapy — The gel in use is a composition of Hyaluronic acid, Poloxamer, 2-Phenoxyethanol, Octedine HCL,Water (Pocket-X Gel Geistlich AG, Wolhusen, Switzerland). It is a patented liquid-to-gel device. Pocket-X® Gel is composed of: Poloxamer 407 with thermo-gelling properties, Octenidine, antimicrobial preservative, Hyaluronic acid to support tissue healing. It promotes gingival healing and prevents bacterial recolonization of periodontal pockets, forming a protective physical barrier, allows to postpone or avoid long, complex and painful surgeries, ensuring the success of periodontal treatment, delaying any surgical interventions.

Primary Outcomes

  • Clinical evaluation, in the test site and in the control site (for each of the two groups) of the periodontal index of: PPD in mm. (At baseline and after 2 weeks, 1 month, and 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-02
Completion: 2030-01
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universita di Verona
Contact Information
Study Contact:
Alessia Pardo
+39 3494628471
Alessia.pardo@univr.it
Interventions
  • Device: Gel therapy after non surgical therapy — The gel in use is a composition of Hyaluronic acid, Poloxamer, 2-Phenoxyethanol, Octedine HCL,Water (Pocket-X Gel Geistlich AG, Wolhusen, Switzerland). It is a patented liquid-to-gel device. Pocket-X® Gel is composed of: Poloxamer 407 with thermo-gelling properties, Octenidine, antimicrobial preservative, Hyaluronic acid to support tissue healing. It promotes gingival healing and prevents bacterial recolonization of periodontal pockets, forming a protective physical barrier, allows to postpone or avoid long, complex and painful surgeries, ensuring the success of periodontal treatment, delaying any surgical interventions.
Study Locations (1 sites)
Alessia Pardo 3494628471 Alessia.pardo@univr.it, Verona, Italy 37134 Italy
Eligibility Criteria
Inclusion Criteria: Patients normally eligible for the visit and for the non-surgical type of treatment for periodontal defects: * patients with an age between 18 and 80; * patients with: (i) Asa status I (no functional impairment due to pathologies), (ii) patients with type 2 diabetes (T2DM) with: glycated hemoglobin level HbA1c between 6.5 and 8.0%, on dietary therapy and/or with hypoglycemic drugs in regular follow-up at the diabetes service; * patients with chronic periodontitis stage 3 or 4, according to the new classification of periodontal diseases \[Tonetti et al.\]), verified clinically and radiographically: patients will be selected with interdental clinical attachment level (CAL) at the site of greatest loss ≥3 mm to ≥2 non-adjacent teeth, probing depth (PPD) ≥5 mm, bleeding on probing (BoP) and horizontal and/or vertical radiographic bone loss. Exclusion Criteria: * Patients not eligible for the non-surgical type of treatment for periodontal defects: * patients with a positive history of diseases with functional impairment (ASA status 2,3,4) or severe handicaps that could limit the ability to attend appointments; * patients with uncontrolled/poorly controlled DM at the time of study selection (e.g. type 1 diabetes mellitus and secondary forms of diabetes); patients with uncontrolled and serious diabetic complications (cardiovascular, renal, hepatic and nervous); * poor compliance with treatment, with poor oral hygiene and motivation; * not signing informed consent by patients.
Conditions Diabetes Mellitus, Type 2, Lifestyle Ris...
Phase NA
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

We aim to provide medical nutritional therapy to patients with type 2 diabetes who are on oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with flash glucose monitoring or self-monitoring of blood glucose. Specifically, this is a randomized, open-label, controlled study where half of the study participants will have FreeStyle Libre device on for 12 weeks and compare the change in glycated hemoglobin (HbA1c) value with the patients in the control group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: FreeStyle Libre — Flash glucose monitoring + Education on lifestyle modification
  • Device: Blood glucose meter — Self monitoring of blood glucose + Education on lifestyle modification

Primary Outcomes

  • Change in HbA1c (Baseline to Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-03-23
Completion: 2023-03-23
Eligibility
Age: 19 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Hospital
Collaborators: Inje University, Kangbuk Samsung Hospital
Principal Investigators:
  • Young Min Cho, MD, PhD (PRINCIPAL_INVESTIGATOR) - Seoul National University Hospital
Contact Information
Study Contact:
Hun Jee Choe, MD
82-2-2072-1965
hunjeechoe@snu.ac.kr
Young Min Cho, MD, PhD
82-2-2072-1965
ymchomd@snu.ac.kr
Young Min Cho, MD, PHD
82-2-2072-1965
ymchomd@snu.ac.kr
Seoul National University Hospital
Interventions
  • Device: FreeStyle Libre — Flash glucose monitoring + Education on lifestyle modification
  • Device: Blood glucose meter — Self monitoring of blood glucose + Education on lifestyle modification
Study Locations (1 sites)
Seoul National University Hospital, Seoul, 110-744 South Korea
Eligibility Criteria
Inclusion Criteria: * Age 19-80 * Diagnosed with type 2 diabetes mellitus (DM) * Uncontrolled type 2 DM: HbA1c 7.0-10.0% * Signed informed consent Exclusion Criteria: * Diagnosed with other types of diabetes mellitus (i.e. Type 1 DM) * Use of prandial insulin * Change in diabetes medication in the preceding 3 months * Pregnant/lactating women * Addiction to drugs and alcohol * Use of medications that result in drug-induced hyperglycemia (i.e. steroid) * Severe liver disease * End-stage renal disease (i.e. on dialysis) * Unable to wear CGM devices due to dermatologic side effects (i.e. severe burn, inflammation, active skin infection, severe skin reactions, hypertrichosis, etc.) * Conditions that impact the stability of HbA1c measurement
Conditions Asthma
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this longitudinal observational study is to learn if impulse oscillometry (IOS) has an added value in asthma monitoring in adult asthma patients who are prescribed a change in asthma maintenance therapy. The main questions it aims to answer are: * Is there a difference in the change in IOS parameters and FEV1 respectively, stratified according to change in asthma control test? * Is there a difference in the change in IOS parameters and FEV1 respectively, stratified according to change in other questionnaire such as the asthma control questionnaire and the asthma quality of life questionnaire. * Are the proposed minimal clinically important differences (MCIDs) valid for short follow-up periods (3 - 6 months)? Participants will undergo lung function testing (full lung function, multiple breath nitrogen washout, impulse oscillometry) and questionnaires (asthma control test, asthma control questionnaire, asthma quality of life questionnaire), once during the baseline visit and once during the follow-up visit three to six months later.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Full lung function — This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
  • Other: Multiple breath nitrogen washout — Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
  • Other: Impulse oscillometry — Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.

Primary Outcomes

  • Change in frequency dependance of resistance (FDR) stratified according to change in asthma control test (ACT) (Once at baseline and 3 - 6 months later during follow-up)
  • Change in area of reactance (AX) stratified according to change in asthma control test (ACT) (Once at baseline and 3 - 6 months later during follow-up)
  • Change in forced expiratory volume in 1 second (FEV1) stratified according to change in asthma control test (ACT) (Once at baseline and 3 - 6 months later during follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-01
Completion: 2026-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitair Ziekenhuis Brussel
Collaborators: Vrije Universiteit Brussel
Contact Information
Study Contact:
Shane Hanon, Prof. Dr. MD.
02 477 6841
Shane.Hanon@uzbrussel.be
Interventions
  • Other: Full lung function — This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
  • Other: Multiple breath nitrogen washout — Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
  • Other: Impulse oscillometry — Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.
Study Locations (1 sites)
Universitair Ziekenhuis Brussel, Brussels, 1090 Belgium
Eligibility Criteria
Inclusion Criteria: * Adult asthma patients with a scheduled consultation at the outpatient hospital to whom a step-up or step-down of their pharmacological asthma treatment is prescribed Exclusion Criteria: * Unstable asthma (defined as need for oral corticosteroids or (respiratory) antibiotic course in the 4 weeks before inclusion or any major medical issue in the 4 weeks before inclusion)
Conditions Chronic Rhinosinusitis With Nasal Polyps...
Phase Not Applicable
Enrollment 57
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Mepolizumab is a biologic agent already approved for severe asthma. Recently, there is increasing evidence concerning the benefit of anti-IL5 treatments upon patients with nasal polyposis with or without severe asthma. The novelty of this project is that no biologic agent has yet been fully investigated to identify any biomarkers of response for patients with nasal polyps with or without asthma including sinonasal tissue remodeling a key element in the resultant histopathological changes of the inflammation. The investigation of airway remodeling of various locations (nose and bronchus) under mepolizumab treatment will be our primary objective on the long-term basis of 156 weeks of treatment. Endobronchial and nasal biopsies will be performed as routine care for tissue evauation and disease investigation for every patient. Besides, the united airways will provide better guidance for medical treatment of chronic rhinosinusitis (CRS) patients with nasal polyps (CRSwNP) and asthma. The initial idea is based on investigating the characteristics that could predict the effectiveness of mepolizumab on patients with nasal polyposis with or without asthma. Patients will receive 39 doses of mepolizumab for 156 weeks. An additional aim of this study is to identify characteristics of non-responders and responders to mepolizumab. Responders will be identified based on airway remodeling status, biomarkers in tissue and secretion samples and on the reduction of the need of surgery through Lund-Kennedy endoscopic score, Lund-Mackay score and patient's clinical status in the 6th, 12th and 36th month after the initiation of treatment. Regarding the unified airway system, nose and pharyngeal microbiome will be evaluated before and after 52 weeks of mepolizumab treatment in patients with nasal polyps whereas in patients with nasal polyps and asthma bronchus microbiome will also be evaluated. Lung samples will help gain information about the inflammatory profile and local microbiome of CRSwNP patients with asthma through molecular and cellular assays. The human Pharyngeal Microbiome might play a protective role in Respiratory Tract Infections and it has been reported that the microbiome provides critical signals to promote maturation of immune cells and differentiation of the tissue. Thus, we will make an effort to correlate microbiome of various locations with clinical and laboratory characteristics of responders and non-responders to mepolizumab treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Mepolizumab 100 MG [Nucala] — subcutaneous injection once a month

Primary Outcomes

  • Change in Basement Membrane Thickness (through study completion, 156 weeks)
  • Change in smooth muscle cell mass (through study completion, 156 weeks)
  • Change in microbiome (through study completion, 156 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-23
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 57 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aristotle University Of Thessaloniki
Collaborators: Department of Otorhinolaryngology, Head and Neck Surgery, George Papanikolaou Hospital, Department of Otorhinolaryngology, Democritus University of Thrace, Alexandroupolis, Department of Pulmonology, Democritus University of Thrace, Alexandroupolis, Respiratory Medicine Department, University of Ioannina, Faculty of Medicine, National and Kapodistrian University of Athens, Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Department of Otolaryngology, Head and Neck Surgery, Sotiria General Hospital
Principal Investigators:
  • Konstantinos Porpodis, Assoc Prof (PRINCIPAL_INVESTIGATOR) - Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital
Contact Information
Study Contact:
Konstantinos Porpodis, Assoc Prof
00306944728818
kporpodis@yahoo.gr
Kalliopi Domvri, Dr
00306940904246
kdomvrid@auth.gr
Konstantinos Porpodis, Asist Prof
2313307258
kporpodis@yahoo.gr
Pulmonary Clinic of Aristotle University of Thessaloniki, George Papanikolaou Hospital
Interventions
  • Drug: Mepolizumab 100 MG [Nucala] — subcutaneous injection once a month
Study Locations (2 sites)
Pulmonary Clinic of Aristotle University of Thessaloniki, George Papanikolaou Hospital, Thessaloniki, Exochi 57010 Greece
University Pulmonary Clinic, George Papanikolaou Hospital, Thessaloniki, 57010 Greece
Eligibility Criteria
Inclusion Criteria: * Adult patients \> 18 years with bilateral Nasal Polyps * Symptoms VAS scores (for nasal obstruction, hyposmia, post-nasal drip, sneezing, rhinorrhea; 0-10 for each symptom) \> 24 in spite of treatment with standard of care treatment. * Patients with bilateral sinonasal polyps with a need for surgery as described by: Lund-Mackay score \> 4, Lund Kennedy score \> 6, a minimum total Nasal polyp score of 5 out of a maximum score of 8 at screening, ongoing symptoms for at least 12 weeks prior to screening, * Concerning patients with asthmatics with nasal polyps: subjects must have a medical history of asthma as confirmed by asthma related symptoms and by bronchodilator response (BDR) (GINA 2022) or positive methacholine challenge according to ERS guidelines. Exclusion Criteria: * Pregnant or nursing women, or women of child-bearing potential. * Biologic therapy (eg: Omalizumab, Mepolizumab, Reslizumab, Dupilumab) or previous treatment with Mepolizumab * Allergen immunotherapy in the past 6 months * Systemic corticosteroid treatment for other chronic conditions (i.e.: autoimmune disorders, tumors, etc) * Prior/concomitant therapy: use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1 and during the study period. * Evidence of active systemic immunodepression (i.e..: primary or secondary immunodeficiency) * History of malignancy of any organ system or any other serious co-morbidities defined by the treating physician. * Primary diagnosis of lung disease other than asthma (chronic obstructive lung disease (COPD), asthma-COPD overlap (ACO), interstitial lung disease, sarcoidosis, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, active tuberculosis, allergic bronchopulmonary aspergillosis (ABPA), current lung cancer or other blood, lymphatic or solid organ malignancy, autoimmune diseases of the skin, muscle-skeletal or gastrointestinal system needing systemic corticosteroids, immunosuppressants or biologic treatment as well as individuals with granulomatosis with polyangiitis (Wegener's granulomatosis) and eosinophilic granulomatosis polyangiitis (Churg-Strauss syndrome). * Nasal polyps' or Asthma exacerbation, within 12 weeks prior to screening that required oral corticosteroids over 3 days or hospitalization or emergency room visit.
Conditions Chronic Obstructive Lung Disease, Respir...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to understand the role of oestrogen in patients with asthma and Chronic Obstructive Pulmonary Disorder (COPD). Therefore, what is the effect of oestrogen in these participants compared to controls (those without disease). The study hypothesises that oestrogen loss in patients with asthma and COPD causes accelerated lung function decline and changes to lung structure. It will investigate if this is mediated by inflammation, immune host response or elastin and collagen changes. It is an observational prospective cohort study aiming to recruit healthy controls, and people with asthma or COPD), and/or the menopause.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — No Intervention

Primary Outcomes

  • Lung Function (FEV1 change from baseline) (Through study completion, minimum of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-01
Completion: 2028-11-01
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guy's and St Thomas' NHS Foundation Trust
Principal Investigators:
  • Mona Bafadhel (PRINCIPAL_INVESTIGATOR) - King's College London
Contact Information
Study Contact:
Gill Radcliffe Ms, MRes
+442071888070
gillian.radcliffe@gstt.nhs.uk
Chris Mwasuku
Christine.Mwasuku@gstt.nhs.uk
Gillian Radcliffe, MRES
+442071888070
gillian.radcliffe@gstt.nhs.uk
Guys & St Thomas NHS Foundation Trust
Interventions
  • Other: No intervention — No Intervention
Study Locations (1 sites)
Guys & St Thomas NHS Foundation Trust, London, SE1 7EH United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Men and women aged \> 18 years. 2. For female participants: pre-menopausal, peri-menopausal and post-menopausal women can all be included. 3. Participants willing and able to give informed consent for participation in the study. 4. Healthy controls \<10 pack year history (participants without Asthma or COPD). Exclusion Criteria: 1. Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus. 2. Alcohol or recreational drug abuse, is defined as when the use is harmful as per NHS definition. 3. History of psychiatric, medical, or surgical disorders. 4. Pregnant 5. Unable to provide written informed consent 6. History of advanced medical conditions with an expected prognosis of \< 3 years. 7. Patients with a history of active cancer. 8. Patients on long term oxygen (ambulatory oxygen).
Conditions Asthma
Phase Not Applicable
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI inhalers. Furthermore, it will be addressed if the SiA® system can be used to discriminate between patients, where increased inflammatory markers are caused by incorrect inhaler technique/adherence to medication or patients that have ongoing inflammation requiring adjustment of therapy. Potentially those who might become candidate for biological treatments. The main questions it aims to answer are: * Can the SiA® system improve inhaler use and medication adherence in asthma patients? * Does improving inhaler technique and adherence lead to better asthma control and reduced airway inflammation (measured by FeNO levels)? Participants will: * Use the SiA® system, which includes a smart inhaler cap (RespiPRO™) and a mobile app * Continue their prescribed Trimbow pMDI treatment for asthma. * Have their asthma control, lung function, and FeNO levels monitored at specific points over 1 year (3 months and 12 months). The study does not have a comparison group and all results will be compared to baseline.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • To evaluate the impact of the SiA® platform on the level of the type 2 inflammation biomarker FeNO (Change from baseline in FeNO at week 12 and 52.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-15
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chiesi Pharma AB, Nordic
Collaborators: Briota ApS
Principal Investigators:
  • Johannes M Schmid, PhD, ass. professor (PRINCIPAL_INVESTIGATOR) - Aarhus University Hospital
Contact Information
Study Contact:
Nicolai Krogh, PhD
+4526850170
n.krogh@chiesi.com
Charlotte S Ulrik, MD, DMSc, FERS
+4538622177
charlotte.Suppli.Ulrik@regionh.dk
Copenhagen University Hospital-Hvidovre
Charlotte S Ulrik, charlotte.Suppli.Ulrik@regionh
Copenhagen University Hospital-Hvidovre
Interventions
N/A
Study Locations (2 sites)
Copenhagen University Hospital-Hvidovre, Hvidovre, Capital Region DK-2650 Denmark
Aarhus University Hospital, Aarhus, Central Jutland DK-8200 Aarhus N Denmark
Eligibility Criteria
Inclusion Criteria: 1. Patients ≥18 years of age. 2. Objectively verified leading diagnosis of asthma according to GINA 3. FeNO \>25 ppb. 4. Treated with Trimbow 87/5/9 pMDI for \>4 weeks before enrolment, 1. with prescribed rescue medication (SABA). 2. with and without prescription of a spacer. 5. Being literate Danish. 6. Having a personal Android/iOS phone and 4G/5G internet connection. 7. Comfortable using a smart phone and Bluetooth enabled Digital Devices. 8. Willingness to participate in the study, understand the written patient information and being able to provide written informed consent. Exclusion Criteria: 1. Participation in a clinical trial within 4 weeks prior to enrolment into the present study or planned enrolment in a clinical trial during the observational period. 2. Use of systemic corticosteroid as maintenance treatment. 3. Treated with biologics (that is monoclonal antibodies). 4. Concomitant diagnosis of COPD. 5. Lung cancer or history of lung cancer. 6. Respiratory tract infection/exacerbation within 4 weeks prior to enrolment. 7. Use of oral corticosteroids within 4 weeks before enrolment.
Conditions Asthma
Phase Not Applicable
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Increasing evidence supports that the respiratory microbiota, including viral and bacterial microorganisms, play important roles in respiratory health and disease. Microbial patterns in airways may induce distinctive endotypes of asthma. Previous studies suggest host-microbiota interactions in children may account for the heterogeneity of endotypes and clinical presentations. However, information on such relationship is limited in adults. Furthermore, how the upper airway microbiome is related to asthma endotype and phenotype is not well understood. Knowledge of microbiota in the airway allows exploration of therapeutic manipulation of the microbiome and targeting the development of asthma prevention strategies and the optimization of asthma treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Treatment of asthma according to GINA guideline — Pharmacological treatment depending on level of control of asthma

Primary Outcomes

  • Microbiome pattern (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-06-22
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Fanny Ko, MD (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
Fanny Ko, MD
+852 35053133
fannyko@cuhk.edu.hk
David Hui, MD
+852 35053133
dschui@cuhk.edu.hk
Fanny WS KO, MD
fannyko@cuhk.edu.hk
Prince of Wales Hospital
Interventions
  • Other: Treatment of asthma according to GINA guideline — Pharmacological treatment depending on level of control of asthma
Study Locations (1 sites)
Prince of Wales Hospital, Shatin, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Subjects aged between 18 and 80 years and have a diagnosis of asthma according to the Global Initiative for Asthma (GINA) document in 2020. * Asthma is defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 200 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable. Exclusion Criteria: * Patients with respiratory diseases with other known respiratory diseases including chronic obstructive pulmonary disease, bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer * Individuals older than 40 years with a smoking history of more than 10 pack-years or significant biomass exposure * Patients currently randomized in other clinical studies * Pregnant women * Current smokers (who have not quit smoking in the past 1 year) * Systemic and intranasal antibiotics treatment within 4 weeks * Signs and symptoms of respiratory tract infections (upper or lower) within 4 weeks
Conditions Asthma Acute, Asthma Attack
Phase NA
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Asthma exacerbations leading to emergency department visits or hospitalization are associated with a high risk of recurrent exacerbations, poor disease control, and increased healthcare utilization in the months following discharge. Early specialist follow-up during this vulnerable transition period remains limited, and many patients do not receive optimized long-term asthma management. The purpose of this study is to evaluate whether a structured remote asthma clinic intervention initiated shortly after hospital discharge can reduce recurrent exacerbations and improve asthma-related outcomes compared to standard community care. This prospective randomized study will enroll 220 adult patients (18-75 years) presenting to the emergency department at Tel Aviv Sourasky Medical Center with an asthma exacerbation. Participants will be randomly assigned to one of two groups: 1. Intervention group - will undergo two structured remote pulmonology follow-up visits via secure video consultation within 7-21 days and 5 months after discharge, including treatment optimization, inhaler technique assessment, and self-management education. 2. Control group - will continue standard community care without additional intervention. All participants will complete scheduled follow-up assessments over 12 months, including evaluation of exacerbations, asthma control, healthcare utilization, and medication use.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Follow-up in a remote flare-up clinic — Participants assigned to the intervention group will undergo two structured remote pulmonology visits via secure video consultation, conducted 7-21 days and 5 months after discharge following an asthma exacerbation. The intervention will include assessment of asthma control and exacerbation history, inhaler technique evaluation, treatment optimization, and asthma self-management education according to current guidelines. Additional follow-up phone assessments will be conducted at 3, 9, and 12 months for study outcome evaluation only.

Primary Outcomes

  • Asthma Exacerbations Rate (From enrollment to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-01
Completion: 2028-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tel-Aviv Sourasky Medical Center
Collaborators: The Dalia and Eli Hurvitz Foundation Grant
Contact Information
Study Contact:
Amir Bar-Shai
+972-507265248
amirbs@tlvmc.gov.il
Amir Bar-Shai, MD
+972-507265248
amirbs@tlvmc.gov.il
Tel-Aviv Sourasky Medical Center, Tel Aviv
Interventions
  • Other: Follow-up in a remote flare-up clinic — Participants assigned to the intervention group will undergo two structured remote pulmonology visits via secure video consultation, conducted 7-21 days and 5 months after discharge following an asthma exacerbation. The intervention will include assessment of asthma control and exacerbation history, inhaler technique evaluation, treatment optimization, and asthma self-management education according to current guidelines. Additional follow-up phone assessments will be conducted at 3, 9, and 12 months for study outcome evaluation only.
Study Locations (1 sites)
Tel-Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel
Eligibility Criteria
Inclusion Criteria: * Presentation to the emergency department with an asthma exacerbation. * Ability to complete telephone follow-up and access to a personal e-mail account. * Agreement to participate in the study. * Written or verbal informed consent according to study group assignment. Exclusion Criteria: * Uncontrolled cardiac disease. * Any other uncontrolled medical condition. * Inability to complete telephone follow-up. * Pregnancy. * Patients lacking decision-making capacity.
Conditions Asthma in Children, Directly Observed Th...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Children with asthma from communities that experience health inequities frequently do not receive guideline-based asthma care, and as a result, account for a disproportionate percentage of asthma exacerbations, emergency department visits, and hospitalizations. Project ASTHMA (Aligning with Schools To Help Manage Asthma) tests the effectiveness of school-based health centers as a delivery model to improve health outcomes by providing children with guideline-based asthma assessments and preventive medication management, directly observed therapy of their preventive medication to support adherence, and self-management support. If successful, this multicomponent intervention will represent a cost effective and sustainable model to reduce asthma morbidity in historically marginalized communities, and has the potential to impact communities throughout the United States where over 2,500 school-based health centers operate.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: APP assessment and management of asthma — APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.

Primary Outcomes

  • Asthma exacerbations (from 1 month after enrollment to the end of the school year for 1 school year; to be assessed after the end of the school year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-27
Completion: 2028-04-30
Eligibility
Age: 4 Years – 13 Years
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: State University of New York at Buffalo
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Contact Information
Study Contact:
Lucy CY Holmes, MD, MPH
716-323-0034
LHolmes@upa.chob.edu
Deanna Hamilton, MSEd
716-323-0060
DeHamilton@upa.chob.edu
Lucy Holmes, MD, MPH
716-323-0034
LHolmes@upa.chob.edu
University at Buffalo, Department of Pediatrics
Interventions
  • Other: APP assessment and management of asthma — APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
Study Locations (1 sites)
University at Buffalo, Department of Pediatrics, Buffalo, New York 14203 United States
Eligibility Criteria
Inclusion Criteria: * uncontrolled asthma Exclusion Criteria: * other chronic lung disease such as cystic fibrosis
Conditions Asthma (Diagnosis)
Phase PHASE3
Enrollment 416
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with asthma. The purpose of this study is to compare the efficacy and safety of the Beclomethasone Dipropionate and Formoterol Fumarate inhalation aerosol (manufactured by Lunan Better Pharmaceutical Co., Ltd.) with FOSTER® in the treatment of patients with asthma.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Beclometasone Dipropionate and Formoterol Inhalation Aerosol — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
  • Drug: FOSTER® — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.

Primary Outcomes

  • Change from baseline in forced expiratory volume in 1 second (FEV1) at Week 4 (Baseline to Week 4.(at the end of the 4-week treatment period))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-06-08
Completion: 2028-06
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 416 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lunan Better Pharmaceutical Co., LTD.
Contact Information
Study Contact:
Mei Ling Jin
021-31587861
MLjin118@163.com
Zhenju Song
021-31587861
Song.zhenju@zs-hospital.sh.cn
Meiling Jin
021-31587861
MLjin118@163.com
Zhongshan Hospital, Fudan University
Interventions
  • Drug: Beclometasone Dipropionate and Formoterol Inhalation Aerosol — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
  • Drug: FOSTER® — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
Study Locations (1 sites)
Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Male or female aged ≥18 and ≤75 years. 2. Clinically diagnosed with bronchial asthma for at least 3 months at screening (with traceable diagnostic evidence and medical records), and the diagnosis has been confirmed according to the Guidelines for the Prevention and Management of Bronchial Asthma, meeting the following criteria: a) Positive objective test for variable airflow limitation (i.e., meeting any one of the following): (i) Positive bronchodilator reversibility test (i.e., an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from pre-bronchodilator values after inhalation of a bronchodilator; or an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from baseline after 4 weeks of anti-inflammatory therapy with an inhaled corticosteroid, excluding respiratory tract infections); or (ii) Positive bronchial provocation test: commonly using methacholine or histamine as the inhaled provocative agent, with a positive result defined as a ≥20% decrease in FEV₁ after inhalation, indicating airway hyperresponsiveness. (A positive result from any confirmed objective test for variable airflow limitation performed within 1 year prior to signing the ICF is acceptable; if not available, a positive bronchial provocation or bronchodilator reversibility test must be met at screening.) b) Pulmonary function test: FEV₁ ≥40% of predicted value. 3. Within at least 4 weeks prior to signing the ICF, the subject has been on a stable daily dose of an inhaled corticosteroid (ICS) with "as-needed" short-acting β₂-agonist (SABA) use but asthma is not well controlled (ACQ-5 ≥1.00), OR has been on a stable daily dose of an ICS plus a long-acting β₂-agonist (LABA) and asthma is well controlled (ACQ-5 \<1.00). 4. Subjects who use SABA or other reliever medications as needed before screening may be enrolled only if the investigator assesses that they can be switched to the unified rescue medication provided in this study. 5. Willing and able to comply with the protocol requirements and the investigator's instructions for pulmonary function tests, and, after training, able to correctly use the pressurized metered-dose inhaler (pMDI), peak flow meter, and complete the diary card records. 6. Willing to voluntarily participate in this study and sign the informed consent form after full informed consent. Exclusion Criteria: 1. Have intermittent asthma or asthma that occurs only upon occasional exposure to allergens or chemical sensitizers. 2. Have a history of life-threatening asthma (e.g., brittle asthma, admission to the intensive care unit due to an acute asthma exacerbation) within 1 year prior to screening. 3. Have other respiratory system diseases, including but not limited to allergic bronchopulmonary aspergillosis (ABPA), active tuberculosis, pneumonia, pneumothorax, idiopathic pulmonary fibrosis, clinically significant atelectasis, chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia, chronic bronchitis, or other significant pulmonary abnormalities other than asthma (such as cystic fibrosis, bronchiectasis, or alpha-1 antitrypsin deficiency), and are considered by the investigator to be unsuitable for participation in this clinical study. 4. Have a respiratory tract infection of non-viral etiology, sinusitis, or otitis media within 4 weeks prior to screening. 5. Have a history of severe cardiovascular or cerebrovascular diseases, such as congestive heart failure of New York Heart Association (NYHA) class ≥II, unstable angina, coronary heart disease, myocardial infarction, stroke, etc., within 6 months prior to screening; have a prolonged QTc interval (QTc \>450 ms for males or \>470 ms for females, corrected using Fridericia's formula) or have ECG abnormalities that are assessed by the investigator as clinically significant and requiring pharmacological treatment; or have poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg after adequate treatment). 6. Have oral candidiasis identified at screening. 7. Have laboratory test results meeting any of the following criteria: Liver function: alanine aminotransferase (ALT) \>2×ULN and/or aspartate aminotransferase (AST) \>2×ULN, and total bilirubin (TBIL) \>2×ULN; Renal function: serum creatinine \>1.5×ULN; Fasting blood glucose \>10 mmol/L or glycated hemoglobin (HbA1c) ≥8.0%; Serum potassium \<3.5 mmol/L. 8. Have received biological targeted therapy (including anti-IgE monoclonal antibodies such as omalizumab, anti-IL-5 monoclonal antibodies such as mepolizumab, anti-IL-5 receptor monoclonal antibodies such as benralizumab, or anti-IL-4 receptor monoclonal antibodies such as dupilumab) within 5 half-lives prior to entry into the run-in period. 9. Have experienced an asthma exacerbation requiring systemic corticosteroid treatment or have required oral corticosteroid therapy within 4 weeks prior to screening, or have other diseases that require long-term oral or intravenous corticosteroid therapy. 10. Have used beta-blockers (including eye drops), quinidine, disopyramide, procainamide, phenothiazines, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, or any other medications that may prolong the QTc interval and increase the risk of ventricular arrhythmias within 4 weeks prior to screening. 11. Have a history of drug abuse or alcohol abuse within 1 year prior to screening. 12. Are current smokers; have a smoking history of ≥10 pack-years (1 pack = 20 cigarettes); for those with a smoking history of \<10 pack-years, they must have stopped smoking for at least 6 months to be eligible for the study. 13. Have received treatment with any other investigational drug or device in another clinical trial within 3 months prior to screening. 14. Have a known intolerance to or contraindication to beta₂-agonists and/or inhaled corticosteroids, or are allergic to any component of the investigational products. 15. Are pregnant or breastfeeding; or are women of childbearing potential, or male subjects with partners of childbearing potential, who do not agree to use medically recognized effective contraceptive measures (such as an intrauterine device or condom) during the study and for 6 months after the last dose of the investigational product. 16. Meet any of the following conditions prior to randomization: 1. Run-in period compliance \<80% or \>120%; 2. Have an asthma exacerbation during the run-in period (including asthma-related serious adverse events, asthma worsening leading to hospitalization or emergency treatment, unscheduled visits resulting in changes in treatment, etc.); 3. Are considered by the investigator to be unsuitable for randomization.
Conditions Asthma in Children, Asthma Attack
Phase EARLY_PHASE1
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Magnesium Sulfate within the first hour — The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension. 15-19 kg: 750 mg 20-29 kg: 1000 mg 30-39 kg: 1500 mg \>40 kg: 2000 mg
  • Other: No Magnesium sulfate within the first hour — The control group will not receive IV magnesium sulfate within the first hour of treatment.

Primary Outcomes

  • Change in Length of Stay in Patients who receive IV Magnesium within the first hour (experimental group) vs control group (From initiation of therapy to discharge from the emergency department or admitting unit, up to 1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-11-30
Completion: 2025-05-31
Eligibility
Age: 5 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oklahoma
Principal Investigators:
  • Ryan McKee, MD (PRINCIPAL_INVESTIGATOR) - University of Oklahoma
Contact Information
Study Contact:
Ryan McKee, MD
4056308997
ryan-mckee@ouhsc.edu
Jaclyn Urquiola Sorzano, DO
7863906297
jaclyn-urquiola@ouhsc.edu
Ryan McKee, MD
405-271-2429
Ryan-McKee@ouhsc.edu
Oklahoma Children's Hospital
Interventions
  • Drug: Magnesium Sulfate within the first hour — The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension. 15-19 kg: 750 mg 20-29 kg: 1000 mg 30-39 kg: 1500 mg \>40 kg: 2000 mg
  • Other: No Magnesium sulfate within the first hour — The control group will not receive IV magnesium sulfate within the first hour of treatment.
Study Locations (1 sites)
Oklahoma Children's Hospital, Oklahoma City, Oklahoma 73104 United States
Eligibility Criteria
Inclusion Criteria: * Ages 5-17 years old * Presents to the ED with a respiratory score in the "Moderate" range (6 * Parent(s)/Caregiver(s) speak English Exclusion Criteria: * Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients * Patients who are pregnant * Parent(s)/Caregiver(s) do not speak English
Conditions Immunological Disease, Autoimmune Diseas...
Phase Not Applicable
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The study team plans to establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The study team will to apply state-of-the-art approaches to assessing and predicting immunological and clinical responses associated with these standards and prescribed treatments. The approach is twofold. The first component is to establish a robust and flexible biorepository and database that includes demographic, immunologic, exposure and clinical records, and can facilitate research across disciplines, and across other registries affiliated with Mount Sinai. The second component is to address specific key research questions focused on using novel diagnostics to increase the effectiveness of biologic treatment. Most patients will be recruited from the Mount Sinai Therapeutic Infusion Center (TIC), although others receiving infusions elsewhere or at home will be recruited from outpatient Sinai affiliated clinical practices.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Biologics and Clinical Immunology Registry (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-03-03
Completion: 2030-11
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Principal Investigators:
  • Rachel Miller (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine
Contact Information
Study Contact:
Sarah Alvi
212-659-9416
Sarah.Alvi@mssm.edu
Sonia Parmar
973-944-8221
sonia.parmar@mssm.edu
Sarah Alvi
Sarah.Alvi@mssm.edu
Mount Sinai
Interventions
N/A
Study Locations (1 sites)
Mount Sinai, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: * Age 12 years and up. * Able to provide informed consent. * Medical care at Mount Sinai. * Receiving a biologic medication or immune modulator at Mount Sinai, or considered an appropriate negative control or comparison participant by the study team.